Soligenix, Inc. (NASDAQ:SNGX) Sees Large Growth in Short Interest

Soligenix, Inc. (NASDAQ:SNGX) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 44,400 shares, a growth of 21.0% from the November 30th total of 36,700 shares. Currently, 1.8% of the shares of the stock are short sold. Based on an average trading volume of 105,000 shares, the short-interest ratio is currently 0.4 days.

Institutional Trading of Soligenix

An institutional investor recently bought a new position in Soligenix stock. Armistice Capital LLC bought a new position in shares of Soligenix, Inc. (NASDAQ:SNGX) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 80,000 shares of the biopharmaceutical company’s stock, valued at approximately $206,000. Armistice Capital LLC owned about 8.11% of Soligenix as of its most recent SEC filing. 3.60% of the stock is currently owned by institutional investors.

Soligenix Price Performance

SNGX stock traded down $0.08 during trading on Tuesday, hitting $2.83. The stock had a trading volume of 29,526 shares, compared to its average volume of 745,476. Soligenix has a twelve month low of $1.83 and a twelve month high of $19.20. The company’s 50-day moving average price is $3.38 and its two-hundred day moving average price is $3.80. The stock has a market capitalization of $7.10 million, a P/E ratio of -0.38 and a beta of 1.79.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.